Table I.
Study population characteristics
| Study | Study design and setting | Total n of patients (age, years, mean; SD) | Treatment | Telemedicine | |
|---|---|---|---|---|---|
| Remote | In-person | ||||
| Skin condition: Psoriasis | |||||
| Armstrong, 2018 (USA) Armstrong, 2019 Ford, 2019 Young, 2019 |
RCT, outpatient | 148 (49; 14) | 148 (49; 14) | Topical (67.7%), light therapy (35.5%), non-biologic systemic therapy (38.5%), biologics (19.9%) | Asynchronously – store and forward: collaborative connected-health delivery model |
|
| |||||
| Chambers, 2012 (USA) Parsi, 2012 |
RCT, outpatient | 32 (51) | 32 (43) | Not reported | Asynchronously – store and forward: E-medicine platform (RelayHealth®) |
|
| |||||
| Oostveen, 2014 (Netherlands) | CCT, outpatient | 17 (10.2; 4.0) | 17 (11.4; 3.4) | Topical (dithranol combined with ascorbic acid, and Cremor Lanette I) | Synchronously – video calls |
| Skin condition: Atopic dermatitis | |||||
| Armstrong, 2015 (USA) Kornmehl, 2017 |
RCT, outpatient | 78 (27; 10) | 78 (28; 10) | Not reported (systemically treated patients were excluded) | Asynchronously – store and forward: direct-access online website for their dermatologic care |
|
| |||||
| Bergmo, 2009 (Norway) | RCT, outpatient | 50 (4.6; 95% CI 3.7–5.5) | 48 (5.3; 95% CI 4.3–6.3) | Not reported | Asynchronously – store and forward: software that enables a secure messaging system for users |
|
| |||||
| Van Os-Medendorp, 2012 (Netherlands) |
RCT, outpatient | 53 adults (31; 13) 38 parents of children (age children 2.9; 1.7) |
56 adults (32; 11) 45 parents of children (age children 2.7; 1.6) |
Topical | Asynchronously – store and forward: eczema portal including e-consultations with the dermatology nurse |
CCT: controlled clinical trial; CI: confidence interval; RCT: randomized controlled trial; SD: standard deviation.